Diseases

Seattle Genetics confirmed that its collaborator, Takeda Pharmaceutical Company Limited has asserted the fact that European Commission has extended the current conditional marketing…
Read More...

In order to offer a robust, and economically viable solution for anatomical pathology, Enzo Biochem asserted the authentication of a cervical Cancer biomarker detection test offering a…
Read More...

Baxter asserted the approval of U.S. Food and Drug Administration for Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Baxter's premixed medications are manufactured…
Read More...

U.S FDA has granted 510 (k) clearance to Bio-Rad Laboratories for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents…
Read More...

Enzychem Lifesciences Corp asserted that the US Food and Drug Administration has granted Orphan Drug Designation to EC-18 for treating Acute Radiation Syndrome. US FDA Orphan Drug…
Read More...

AstraZeneca and Merck asserted the sanctioning of LYNPARZA tablets for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded…
Read More...

Bristol-Myers Squibb Company asserted new data from a cohort of the Phase 2 CheckMate-142 trial assessing Opdivo and Yervoy for the treatment of patients with DNA mismatch repair…
Read More...

Biohaven Pharmaceuticals declared proceeding with its clinical investigation of BHV-5000 as intimated by the US Food and Drug Administration. Enrollment of subjects has begun for the…
Read More...

Aquestive Therapeutics proclaimed the acceptance of New drug application for clobazam Oral Soluble Film (clobazam OSF) treating seizures associated with Lennox-Gastaut syndrome (LGS) in…
Read More...

QIAGEN N.V declared the U.S FDA's approval of PMA supplement augmenting indications for use of QIAGEN's therascreen EGFR RGQ PCR kit as a diagnostic to direct the use of  Boehringer…
Read More...

In a bid to develop contrast agents with reduced renal toxicity, Ligand Pharmaceuticals set to initiate a program to develop contrast agents with lessened renal toxicity. Enabling usage…
Read More...

Clinical stage company, Relmada Therapeutics into developing novel therapies for treating Centralnervous system diseases obtained global rights to develop and market dextromethadone…
Read More...

US Food and Drug Administration (FDA) has assured priority review of Novartis supplemental Biological License Application (sBLA) for Kymriah suspension for intravenous infusion,…
Read More...

Neurim Pahrmaceuticals and BIOCODEX undertake a license agreement that enlists the fact that BIOCODEX will possess the exclusive marketing rights to market Neurim's Rx paediatric…
Read More...

Genetic screening and counseling services company, Counsyl sought approval from the New York State Department of Health to provide Prelude Prenatal Screen in New York therefore…
Read More...

Vantage Cancer Care Network into providing integrated cancer Care ventured into an agreement with Alliance Cancer Specialists, PC ensuring extensive delivery of top-notch Oncology Care…
Read More...

U.S Diagnostics confirms distribution of the INFINITY Blood Glucose Monitoring System across Western Africa. Located in New York, INFINITY Blood Glucose Monitoring System…
Read More...

Diplomat Pharmacy mets out CABOMETYX treatment for Renal cell carcinoma inflicted on patients as approved by the Food and Drug administration. Formerly approved as a second-line therapy…
Read More...

Global biotech company committed to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, Castle Creek Pharmaceuticals confirmed…
Read More...

Concert Pharmaceuticals asserted that the U.S FDA has offered Fast Track designation for CTP-543, inhibitor for treatment of moderate-to severe Alopecia Areata discerned as a serious…
Read More...